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PIH28 GlaxoSmithKline, Buenos Aires, Argentina
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Education and Research (BMBF), Berlin, Germany
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PIH35 None
PIH36 Thai Health Promotion Foundation, Bangkok, Thailand
PIH37 None
PIH38 None
PIH39 Pfizer Ltd., Tadworth, UK
PIH40 Shire HGT, Cambridge, MA, USA
PIH41 None
PIH42 PFSA, Boulogne, France
PIH43 Fondo de Investigacio´n Sanitaria, Madrid, Spain
PIH44 QualityMetric Incorporated, Lincoln, RI, USA
PIH45 Sanofi Pasteur MSD, Maidenhead, UK
PIH46 None
PIH47 None
PIH48 Bayer Schering Pharma, Berlin, Germany
PIH49 PFSA, Boulogne, France
PIH50 None
PIH51 Federal Ministry of Education and Research, Berlin, Germany
PIH52 None
PIH53 Eli Lilly, Indianapolis, IN, USA
PIH54 None
PIH55 Shiraz University of Medical Sciences, Shiraz, Iran
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PIH63 Pfizer, New York, NY, USA
PIH64 Ethicon, Germany, Germany
PIH65 GlaxoSmithKline Biologicals, Wavre, Belgium
PIH66 None
PIH67 Pfizer, New York, NY, USA
PIH68 Bayer Schering Pharm, Berlin, Germany
PIN1 None
PIN2 Gilead Sciences, Warsaw, Poland
PIN3 Bristol-Myers Squibb, rueil-Malmaison, France
PIN4 Pfizer Inc, New York, NY, USA
PIN5 Novartis Pharmaceuticals Australia, North Ryde, Australia
PIN6 Bristol Myers Squibb, Istanbul, Turkey
PIN7 Janssen Pharmaceutica NV, Beerse, Belgium
PIN8 Bristol Myers Squibb, Istanbul, Turkey
PIN9 None
PIN10 Pfizer Inc, New York, NY, USA
PIN11 Bristol Myers Squibb, Princeton, NJ, USA
PIN12 Pfizer, Collegeville, PA, USA
PIN13 None
PIN14 Novartis Pharma, Basel, Switzerland
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PIN21 Bayer HealthCare Pharma, Moscow, Russia
PIN22 None
PIN23 Abbott SpA, Campoverde di Aprilia, Italy
PIN24 None
PIN26 Abbott Laboratories, Abbott Park, IL, USA
PIN27 None
PIN28 None
PIN29 Pfizer Pharmaceutics Inc., Sa˜o Paulo, Brazil
PIN30 Pfizer Inc, New York, NY, USA
PIN31 Pfizer Inc., New York, NY, USA
PIN32 Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA; Bayer Schering
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Public Health Training Fellowship (630724), Canberra, Australia
PIN43 Abbott Srl, Campoverde di Aprilia (LT), Italy
PIN44 Sanofi Pasteur MSD, Lyon, France
PIN46 Pfizer, Kuala Lumpur, Malaysia
PIN47 None
PIN48 None
PIN49 Pfizer Inc., New York, NY, USA
PIN50 Merck & Co, Whitehouse Station, NJ, USA
PIN51 Pfizer, San Jose, Costa Rica
PIN52 Pfizer Inc., New York, NY, USA
PIN53 Roche Polska Sp. z o.o., Warsaw, Poland
PIN54 Pfizer Canada, Inc., Kirdland, QC, Canada
PIN55 None
PIN56 Roche Farma, Madrid, Spain
PIN57 Pfizer Inc., New York, NY, USA
PIN58 Pfizer, Sa˜o Paulo, Brazil
PIN59 p, San Jose, Costa Rica
PIN60 None
PIN61 Janssen-cilag, Sao Paulo, Brazil
PIN62 Roche Farma, Madrid, Spain
PIN63 Pfizer, San Jose, Costa Rica
PIN64 Pfizer, San Jose, Costa Rica
PIN65 GlaxoSmithKline GmbH, Munich, Germany
PIN66 Janssen Cilag Farmaceutica, Sa˜o Paulo, Brazil
PIN67 None
PIN68 Merck & Co., Inc, Moscow, Russia
PIN69 Sanofi Pasteur MSD, Lyon, France
PIN70 Sanofi Pasteur, Lyons, France
PIN71 Bayer HealthCare Pharma, Moscow, Russia
PIN72 Dutch Higher Education, Den Haag, The Netherlands
PIN73 Bristol-Myers Squibb, Rueil-Malmaison, France
PIN74 Sanofi Pasteur MSD, Lyon, France
PIN75 Sanofi Pasteur, Lyon, France
PIN76 Pfizer Pharmaceutics Inc., Sa˜o Paulo, Brazil
PIN77 Astellas Pharma Europe Ltd., Staines, UK
PIN78 None
PIN79 Gilead, Warszawa, Poland
PIN80 AstraZeneca, Wedel, Germany
PIN81 Shanghai Roche, Shanghai, China
PIN82 Bristol-Myers Squibb, Mu, Germany
PIN83 Roche Polska Sp. z o.o., Warsaw, Poland
PIN84 Abbott SpA, Campoverde di Aprilia, Italy
PIN85 None
PIN86 Fundacio´ IMIM, Barcelona, Spain
PIN87 Janssen Cilag Farmaceutica, Sao Paulo, Brazil
PIN88 None
PIN89 Bristol-Myers Squibb, Paris, France
PIN90 Janssen Cilag, Neuss, Germany
PIN91 None
PIN92 Roche, Madrid, Spain
PIN93 None
PIN94 None
PIN95 Instituto de Salud Carlos III, ISCIII GR09/0026, Madrid, Spain
PIN96 Institute for Health Management, National Institutes of Health, Ministry of
Health, Kuala Lumpur, Malaysia
PIN97 None









PIN107 Novartis Canada, Montreal, QC, Canada
PIN108 Janssen-Cilag GmbH, 41470 Neuss, Germany
PIN109 2GlaxoSmithKline Biologicals, Wavre, Belgium
PIN110 CRUCELL, Berne, Switzerland
PIN111 None
PIN112 Pfizer SLU, Madrid, Spain
PIN113 ANRS, Paris, France; Health Secretariat of the State of Sa˜o Paulo, Sa˜o
Paulo, Brazil; DRCD, Paris, France
PMD1 alcon france, Rueil-Malmaison, France
PMD2 National Institute for Health Research (NIHR) Health Technology Appraisal
programme, Southampton, UK
PMD3 National Institute for Health Research (NIHR) Health Technology Programme,
Southampton, UK
PMD4 None
PMD5 National Institute for Health Research (NIHR) Health Technology Programme,
Southamptom, UK
PMD6 Medtronic International, Tolochenaz, Switzerland
PMD7 Roche Diagnostics, Mannheim, Germany
PMD8 None
PMD9 Bayer, Sa˜o Paulo, Brazil
PMD10 St. Jude Medical, St. Paul, MN, USA
PMD11 Medtronic, Madrid, Spain
PMD12 Johnson&Johnson Medical, Madrid, Spain
PMD13 Cordis Corporation, Bridgewater, NJ, USA
PMD14 Cordis Corporation, Bridgewater, NJ, USA
PMD15 Biotronik SE & Co KG, Berlin, Germany
PMD16 Novartis, Basel, Switzerland
PMD17 None
PMD18 Medtronic International, Tolochenaz, Switzerland
PMD19 None
PMD20 Medtronic, France, France
PMD21 MEDTRONIC ITALIA, Milan, Italy
PMD22 Johnson & Johnson, Madrid, Spain
PMD23 The Netherlands Organisation for Health Research and Development, The
Hague, The Netherlands
PMD24 3M Skin & Wound Care Division, Neuss, Germany
PMD25 Edwards Lifesciences, Milano, Italy
PMD27 Medtronic, Madrid, Spain
PMD28 Netherlands Leprosy Relief Agency, Jos, Nigeria
PMD29 Bayer, Sa˜o Paulo, Brazil
PMD30 Medtronic International Trading Sarl, Tolochenaz, Switzerland
PMD31 Bayer, Barcelona, Spain
PMD32 None
PMD33 None
PMD34 MITACS, Hamilton, ON, Canada
PMD35 Johnson & Johnson Medical, Madrid, Spain
PMD36 alcon france, Rueil-malmaison, France
PMD37 alcon france, Rueil-malmaison, France
PMD38 Critical Diagnostics, San Diego, CA, USA
PMD39 None
PMD40 St. Jude Medical, St. Paul, MN, USA
PMD41 None
PMD42 Ministry of Higher Education, Kuala Lumpur, Malaysia
PMD43 Therakos, Madrid, Spain
PMD44 Ministry of Higher Education, Kuala Lumpur, Malaysia
PMD45 Medtronic International Sarl, Tolochenaz, Switzerland
PMD46 Apex Pharma Kft., Budapest, Hungary
PMD48 HeartWare Inc., Framingham, MA, USA
PMD49 NIHR, HTA programme, London, UK
PMD50 None
PMD51 Bayer HealthCare Pharmaceuticals, Berlin, Germany
PMD52 Biotronik SE & Co KG, Berlin, Germany
PMD53 Medtronic France SAS, Boulogne Billancourt, France
PMD54 AstraTech, Mölndal, Sweden
PMD55 AstraTech, Mölndal, Sweden
PMD56 Baxter Healthcare, Westlake Village, CA, USA
PMD57 GE HealthCare, Chalfont St Giles, UK
PMD58 German Federal Ministry of Education and Research, Berlin, Germany
PMD59 Medtronic, Tolochenaz, Switzerland
PMD60 GlaxoSmithKline, Research Triangle Park, NC, USA
PMD61 Taipei City Hospital, Taipei, Taiwan; Buddhist Tzu Chi General Hospital,
Taipei Branch, New Taipei, Taiwan
PMD62 Astellas, Deerfield, IL, USA
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PMD65 None
PMD66 Biotronik SE & Co KG, Berlin, Germany
PMD67 Edwards Lifesciences, Newbury, UK
PMD68 Abbott Vascular, Santa Clara, CA, USA
PMD69 AstraTech, Mölndal, Sweden
PMD70 None
PMD71 Biotronik SE & Co KG, Berlin, Germany
PMD72 None
PMD73 National Institutes of Health, Bethesda, NM, USA
PMD74 Baxter Healthcare Corporation, Braine l’Alleud, Belgium
PMD75 Roche Diagnostics, Bratislava, Slovak Republic
PMD76 Quintiles, Hoofddorp, The Netherlands
PMD77 None
PMD78 ZonMW, Den Haag, The Netherlands
PMD79 Center for Translational Molecular Medicine (CTMM), Eindhoven,
Netherlands; Netherlands Heart Foundation, The Hague, The Netherlands
PMD80 ETHICON, Livingston, UK
PMD81 Center for Translational Molecular Medicine, Eindhoven, The Netherlands
PMD82 Medtronic, Milan, Italy
PMD83 The National Institute for Health Research Health Technology Assessment,
Southampton, UK
PMD84 None
PMD85 Pfizer Inc., New York, NY, USA
PMD86 None
PMH1 None
PMH2 University of the Basque Country, UPV/EHU, Leioa, Spain
PMH3 Eli Lilly and Company, Indianapolis, IN, USA
PMH4 Eli Lilly and Company, Indianapolis, IL, USA
PMH5 Eli Lilly and Company, Indianapolis, IN, USA
PMH6 Janssen, Neuss, Germany
PMH7 Lundbeck SAS, Issy les Moulineaux, France
PMH8 None
PMH9 National Research Foundation (NRF), Pretoria, South Africa
PMH10 Florida Agency for Health Care Administration, Tallahassee, FL, USA
PMH11 University of Utah Interdisciplinary Seed Grant, Salt Lake City, UT, USA
PMH12 Eli Lilly and Company, Indianapolis, IN, USA
PMH13 Eli Lilly and Company, Indianapolis, IN, USA
PMH14 TEVA Innovative Espan˜a, Madrid, Spain
PMH15 Bayer HealthCare Pharmaceuticals, Berlin, Germany
PMH16 Reckitt Benckiser Pharmaceuticals, Madrid, Spain
PMH17 AstraZeneca, Warsaw, Poland
PMH18 AstraZeneca, Warsaw, Poland
PMH19 Janssen Pharmaceuticals, Birkerød, Denmark
PMH20 None






PMH26 Ge´nome Que´bec, Montreal, QC, Canada; Ge´nome Canada, Montreal, QC,
Canada
PMH27 Reckitt Benckiser, Slough, UK
PMH29 AstraZeneca, Istanbul, Turkey
PMH31 Eli Lilly (HTA ACE-J Group), Indianapolis, IN, USA
PMH32 None
PMH33 Janssen, Madrid, Spain
PMH34 Sanofi, Warszawa, Poland
PMH35 Janssen Pharmaceutica, Beerse, Belgium
PMH36 Bayer Vital GmbH, Leverkusen, Germany
PMH37 Lundbeck SAS, Issy-les-Moulineaux, France
PMH38 Reckitt Benckiser Healthcare (Italy) SpA – Drug Business Unit., Milan, Italy
PMH39 ZonMW , Den Haag, The Netherlands
PMH40 Servier Laboratories (Aust) Pty Ltd., Hawthorn, Australia
PMH42 Janssen Korea, Seoul, South Korea
PMH43 Takeda Pharmaceutical Company, Deerfield, IL, USA
PMH44 Advanced Pain Centers, S.C., Hoffman Estates, IL, USA
PMH45 None
PMH46 Janssen-Cilag B.V., Tilburg, The Netherlands
PMH47 Novartis Farmace´utica, S.A., Barcelona, Spain
PMH48 AstraZeneca, Madrid, Spain
PMH49 Astrazeneca, Wilmington, DE, USA
PMH50 Reckitt Benckiser Pharmaeuticals, Richmond, VA, USA
PMH51 None
PMH52 None
PMH53 Instituto Salud Carlos III. FIPSE 3035/99, FIS 00/1017, Madrid, Spain; DIUE
Generalitat de Catalunya. 2009 SGR 718, Barcelona, Spain
PMH54 None
PMH55 Takeda Pharmaceutical Company, Deerfield, IL, USA
PMH56 Roche, Basel, Switzerland
PMH57 Takeda Pharmaceutical Company, Deerfield, IL, USA
PMH58 Pfizer, Madrid, Spain
PMH59 Eli Lilly and Company, Indianapolis, IN, USA
PMH60 Lundbeck, Issy-les-Moulineaux, France
PMH61 Shire Pharmaceuticals, Inc, Wayne, PA, USA
PMH62 Takeda Pharmaceutical Company, Deerfield, IL, USA
PMH63 None
PMH64 NHRI, Jhunan, Taiwan
PMH65 AstraZeneca, Södertälje, Sweden
PMH66 None
PMH67 IMS Health Sweden AB, Stockholm, Sweden
PMH68 AstraZeneca, Södertälje, Sweden
PMH69 ”Prends soin de toi” Program, Montre´al, QC, Canada
PMH70 Glaxosmithkline, Paris, France
PMH71 AstraZeneca Pharmaceuticals, L.P, Wilmington, DE, USA
PMH72 AstraZeneca Pharmaceuticals, LP, Wilmington, DE, USA
PMH73 vdek Baden-Wuerttemberg, Stuttgart, Germany; KV BaWue,
Stuttgart/Karlsruhe, Germany
PMH74 Universitat Polite`cnica de Vale`ncia, Valencia, Spain
PMH75 Reckitt Benckiser Pharmaeuticals, Richmond, VA, USA
PMH76 Lundbeck A/S, Copenhagen, Denmark
PMH77 Manipal University, Manipal, India; Association of Community
Pharmacists of India, Manipal, India
PMH78 Manipal University, Manipal, India; ACPI, Manipal, India
PMH79 National Institute of Mental Health, Bethesda, MD, USA
PMH80 Lundbeck SAS, Issy-les-Moulineaux, France
PMH81 Lundbeck, Hamburg, Germany
PMH82 None
PMH83 None
PMH84 Pfizer, Madrid, Spain
PMS1 None
PMS2 AHW, Edmonton, AB, Canada
PMS3 Eli Lilly and Company, Indianapolis, IN, USA
PMS4 Auxilium, Malvern, PA, USA
PMS5 None
PMS6 Roche, Woerden, The Netherlands
PMS7 None
PMS8 Eli Lilly and Company, Indianapolis, IN, USA
PMS9 DePuy Mitek, Inc., Raynham, MA, USA
PMS10 None
PMS11 Pfizer, Rome, Italy
PMS12 BristolMeyerSquibb Italia, Rome, Italy
PMS13 Pfizer, Moscow, Russia
PMS14 Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by
Wyeth, which was acquired by Pfizer Inc. in October 2009, Thousand Oaks,
CA, USA
PMS15 Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by
Wyeth, which was acquired by Pfizer Inc. in October 2009, Thousand Oaks,
CA, USA
PMS16 Janssen-Cilag, Neuss, Germany
PMS17 None
PMS18 None
PMS19 Amgen Hellas, Marousi, Greece
PMS20 None
PMS21 Ministry of Health and Welfare, Seoul, South Korea
PMS22 Amgen Canada Inc., Mississauga, ON, Canada
PMS23 Ministry of Health, Labor and Welfare, Tokyo, Japan
PMS24 Abbott Labs, Istanbul, Turkey
PMS25 None
PMS26 Pfizer, New York, NY, USA
PMS27 Amgen CEE HO, Vienna, Austria
PMS28 Amgen CEE HO, Vienna, Austria
PMS29 Bristol-Myers Squibb, Rueil Malmaison, France
PMS30 Roche Farmaceˆutica Quı´mica, Lda., Amadora, Portugal
PMS31 Bristol Myers Squibb Pharmaceuticals, London, UK
PMS32 Pfizer Brazil, Sao Paulo, Brazil
PMS33 None
PMS34 UCB Mexico, Mexico, Mexico
PMS35 Amgen Hellas, Athens, Greece
PMS36 Pfizer Brazil, Sao Paulo, Brazil
PMS37 HFA Healthcare, Birmingham, UK
PMS38 MedImmune LCC, Gaithersburg, MD, USA
PMS39 None
PMS40 Pfizer Brazil, Sao Paulo, Brazil
PMS41 MSD Australia, Sydney, Australia
PMS42 None
PMS43 Pfizer Portugal, Lisbon, Portugal
PMS44 Amgen, Cambridge, UK
PMS45 UCB, Bruxelles, Belgium
PMS46 UCB, Madrid, Spain
PMS47 Merck, Whitehouse Station, NJ, USA
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PMS56 Centre for Public Affairs Studies Foundation, Budapest, Hungary; Roche
Hungary, Budapest, Hungary; TA´MOP 4.2.1/B-09/1/KMR-2010-0005,
Budapest, Hungary
PMS57 Eli Lilly and Company, Indianapolis, IN, USA
PMS58 Eli Lilly and Company, Indianapolis, IN, USA
PMS59 Merck & Co., Inc., Whitehouse Station, NJ, USA
PMS60 Eli Lilly and Company, Indianapolis, IN, USA
PMS61 UCB, Brussels, Belgium
PMS62 Celgene Corporation, Warren, NJ, USA
PMS63 USB, Monheim, Germany
PMS64 Pfizer, Tadworth, UK
PMS65 Graduate School of Chulalongkorn University, Bangkok, Thailand
PMS66 Eli Lilly and Company, Indianapolis, IN, USA
PMS67 None
PMS68 Abbott Greece, Athens, Greece
PMS69 None
PMS70 Eli Lilly and Company, Indianapolis, IN, USA
PMS71 None
PMS72 Eli Lilly and Company, Indianapolis, IN, USA
PMS73 Pfizer, Moscow, Russia
PMS74 None
PMS75 Merck, Sharp & Dohme, Pac¸o de Arcos (Oeiras), Portugal
PMS76 DePuy Mitek, Inc., Raynham, MA, USA
PMS77 Washington State Department of Labor and Industries, Olympia, WA, USA
PMS78 Medtronic Inc, Tolochenaz, Switzerland
PMS79 Bristol Myers Squibb Pharmaceuticals, London, UK
PND1 Biogen Idec, Wellesley, MA, USA
PND2 Teva Neuroscience Inc, Hersham, PA, USA




PND7 NOVARTIS PHARMA AG, Basel, Switzerland
PND8 PFSA, Boulogne, France
PND9 TEVA Innovative Espan˜a, Madrid, Spain
PND10 Biogen Idec, Weston, MA, USA
PND11 TEVA Pharma, Madrid, Spain
PND12 GlaxoSmithKline, Research Triangle Park, NC, USA; Human Genome
Services, Rockville, MD, USA
PND13 GlaxoSmithKline, Marly le Roi, France
PND14 Instituto de Salud Carlos III, Madrid, Spain
PND15 Allergan Singapore, Singapore, Singapore
PND16 Novartis Slovakia, Bratislava, Slovak Republic
PND17 Novartis Pharmaceuticals, Basel, Switzerland







PND25 Laboratoire GlaxoSmithKline, Marly le Roi, France
PND26 Teva Pharmaceuticals, Kansas City, MO, USA
PND27 IPSEN, Paris, France
PND28 TEVA PHARMA, MADRID, Spain
PND29 None
PND30 Almirall, Barcelona, Spain
PND31 Shire Australia Pty Limited, North Ryde, Sydney, Australia
PND32 GSK, Warszawa, Poland
PND33 Novartis Pharma B.V, Arnhem, The Netherlands
PND34 UCB, Brussels, Belgium
PND35 Novartis, Vilvoorde, Belgium
PND36 sanofi-aventis, Bridgewater, NJ, USA
PND37 Teva Pharmaceuticals, Kansas City, MO, USA
PND38 Neurosearch, Copenhagen, Denmark
PND39 Shire Australia Pty Ltd., North Ryde, Sydney, Australia
PND40 Merck & Co., Inc, West Point, PA, USA
PND41 None
PND42 Sanofi-aventis, Bridgewater, NJ, USA
PND43 Astellas Pharma Global Development, Leiderdorp, The Netherlands
PND44 Shire, Cambridge, MA, USA
PND45 PatientsLikeMe, Inc., Cambridge, MA, USA; Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA
PND46 Neurosearch, Copenhagen, Denmark
PND47 Neurosearch, Copenhagen, Denmark
PND48 PFSA, Boulogne, France
PND49 None
PND50 University of Georgia, College of Pharmacy, Department of Clinical and
Administrative Pharmacy, Athens, GA, USA
PND51 Allergan, Irvine, CA, USA
PND52 Merck Serono, Geneva, Switzerland
PND53 Biogen Idec, Weston, MA, USA
PND54 Medtronic International Trading Sarl, Tolochenaz, Switzerland
PND55 None
PND56 None
PND57 Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA
PND58 Shire HGT, Basingstoke, UK
PND59 None
PND60 Teva Pharmaceuticals, Kansas City, MO, USA
PND61 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PND62 None
PND63 GlaxoSmithKline GmbH & Co. KG, Munich, Germany
PND64 Bayer HealthCare, Wayne, NJ, USA
PND65 None
PND66 CAPES, Ribeirao Preto, Brazil
PND67 None
PND68 EAHC, Luxembourg, Luxembourg
PRM1 None






PRM8 Chulalongkorn University, Bangkok, Thailand
PRM9 Costello Medical Consulting, Cambridge, UK
PRM10 None
PRM11 Symmetron limited, Elstree, UK
PRM12 None
PRM13 None
PRM14 TI Pharma, Leiden, The Netherlands; Utrecht University, Utrecht, The
Netherlands; University Medical Center Utrecht, Utrecht, The Netherlands;
GSK, Zeist, The Netherlands; University Medical Center Groningen,
Groningen, The Netherlands; Groningen University, Groningen, The
Netherlands; Sanofi-Aventis, Gouda, The Netherlands
PRM15 None
PRM16 None
PRM17 Departament de Salut de la Generalitat de Catalunys, Barcelona, Spain;
AGAUR (2009 SGR 1095), Barcelona, Spain
PRM18 None




PRM23 UK NHS Health Technology Assessment (HTA) Programme, Southampton,
UK
PRM24 None
PRM25 Sanofi-aventis, Paris, France
PRM26 the university of Sheffield, Sheffield, UK
PRM27 None
PRM28 HTA Consulting, Krakow, Poland
PRM29 None
PRM30 PatientsLikeMe, Cambridge, MA, USA
PRM31 None
PRM32 ZonMW, The Hague, The Netherlands





PRM38 University of Sheffield, Sheffield, UK
PRM39 None
PRM40 None
PRM41 University of Sheffield, Sheffield, UK
PRM42 None








PRM51 HealthCore, Inc., Wilmington, DE, USA





A518 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 5 1 1 - A 5 2 0
PRM53 None






PRM60 Bristol-Myers Squibb, Lawrenceville, NJ, USA
PRM61 None
PRM62 National Institute for Health Research, London, UK





PRM68 Hospital Quiron Bizkaia, Bilbao, Spain
PRM69 None
PRS1 Pfizer Pharmaceutics Inc., Sa˜o Paulo, Brazil
PRS2 Adheris, Inc., Burlington, MA, USA
PRS3 Talecris Biotherapeutics, Frankfurt, Germany
PRS4 Instituto de Salud Carlos III, Madrid, Spain
PRS5 Roche Polska Sp. z o.o., Warsaw, Poland
PRS6 Boehringer Ingelheim GmbH, Ingelheim, Germany
PRS7 Pfizer Brazil, Sao Paulo, Brazil
PRS8 Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
PRS9 Stallergenes GmbH, Kamp-Lintfort, Germany
PRS10 ALK-Abello, Hørsholm, Denmark
PRS11 Stallergenes, Kamp-Lintfort, Germany
PRS12 Chiesi Espan˜a SA, Barcelona, Spain
PRS13 Allergopharma, Reinbek, Germany
PRS14 novartis, Sao Paulo, Brazil
PRS15 Novartis, Sao Paulo, Brazil
PRS16 Nycomed Pharma, Madrid, Spain
PRS17 Basilea Pharmaceutica Ltd., Basel, Switzerland
PRS18 Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
PRS19 Oblikue Consulting, Barcelona, Spain
PRS20 AstraZeneca AB, Södertälje, Sweden
PRS21 Pfizer SLU, Madrid, Spain
PRS22 None
PRS23 Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
PRS24 Pfizer SLU, Madrid, Spain
PRS25 GlaxoSmithKline, Uxbridge, UK
PRS26 None
PRS27 Cegedim Strategic Data Medical Research Ltd., London, UK
PRS28 Novartis, East Hanover, NJ, USA
PRS29 None
PRS30 Novartis Pharmaceuticals Australia, North Ryde, Australia
PRS31 Novartis, Sao Paulo, Brazil
PRS32 Novartis Pharma BV, Arnhem, The Netherlands
PRS33 Pfizer Hellas, Athens, Greece
PRS34 Nycomed Pharma S.A., Madrid, Spain
PRS35 Novartis, Athens, Greece
PRS36 Chiesi Farmaceutici, Parma, Italy
PRS37 GlaxoSmithKline, Moscow, Russia
PRS38 Nycomed, Stockholm, Sweden
PRS39 Nycomed Pharma AG, Du¨bendorf, Switzerland
PRS40 GSK, Warszawa, Poland




PRS45 MSD Ltd., Hoddesdon, UK
PRS46 Organisation Pneumologique pour la Recherche et l’Ame´lioration des Soins
(OPRAS), Paris, France
PRS47 GlaxoSmithKline, Moscow, Russia
PRS48 Pfizer, San Jose, Costa Rica
PRS49 None
PRS50 Novartis Pharma B.V., Arnhem, The Netherlands
PRS51 Forest Research Institute, Jersey City, NJ, USA
PRS52 ZonMW, The Hague, The Netherlands
PRS53 Novartis Pharmaceuticals UK Limited, Camberley, UK
PRS54 GlaxoSmithKline, Uxbridge, UK
PRS55 Novartis Pharmaceuticals UK Limited, Camberley, UK
PRS56 Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
PRS57 GlaxoSmithKline Slovakia, Bratislava, Slovak Republic
PRS58 None
PRS59 Novartis Pharmaceuticlas, Barcelona, Spain





PRS65 Novartis Pharmaceuticals UK Limited, Frimley, UK
PRS66 None
PRS67 Bayer Schering Pharma, Diegem, Belgium
PRS68 Johnson and Johnson Medical Asia-Pacific, Singapore, Singapore
PRS69 None
PRS70 Pfizer UK Ltd., Tadworth, Surrey, UK
PRS71 Pfizer Global Pharmaceuticals, New York, NY, USA
PRS72 GlaxoSmithKline, Verona, Italy
PRS73 Nestle´ Nutrition Institute, Vevey, Switzerland
PRS74 None
PRS75 None
PRS76 GlaxoSmithKline, London, UK
PRS77 Novartis, Horsham, UK
PR1 Novo Nordisk, Søborg, Denmark
PR2 None
PR3 None
PR4 Commonwealth Fund, New York, NY, USA
PSS1 alcon france, rueil-malmaison, France
PSS2 Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada
PSS3 Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada
PSS4 ALCON, Puurs, Belgium
PSS5 ALCON, Puurs, Belgium
PSS6 Bayer Korea, Seoul, South Korea
PSS7 Novartis Pharma A.G., Basel, Switzerland
PSS8 Bristol-Myers Squibb, Uxbridge, UK
PSS9 Novartis Pharma B.V., Arnhem, The Netherlands
PSS10 ALCON, Puurs, Belgium
PSS11 None
PSS12 Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada
PSS13 Celgene Corporation, Summit, NJ, USA
PSS14 Basilea Pharmaceutica International Ltd., Basel, Switzerland
PSS15 None
PSS16 Novartis, Vienna, Austria
PSS17 Novartis Hungary, Budapest, Hungary
PSS18 Allergan Pharmaceuticals Ireland, Westport, Ireland
PSS19 ALCON, Puurs, Belgium
PSS20 Abbott Laboratories, Madrid, Spain
PSS21 Janssen-Cilag A/S, Birkeröd, Denmark
PSS22 None
PSS23 Nestle´ Nutrition Institute, Vevey, Switzerland
PSS24 Janssen, Moscov, Russia
PSS25 Allergan EAME, Marlow, UK
PSS26 Allergan EAME, Marlow, UK
PSS27 Eye Hospital, Rotterdam, The Netherlands
PSS28 Bristol-Myers Squibb, Plainsboro, NJ, USA
PSS29 Celgene Corporation, Summit, NJ, USA
PSS30 Novartis AG, Basel, Switzerland
PSS31 Basilea Pharmaceutica Ltd., Basel, Switzerland
PSS32 Alcon Research Ltd., Basel, Switzerland
PSS33 Basilea, Basel, Switzerland
PSS34 Alcon Laboratories, Fort Worth, TX, USA
PSS35 Alcon Laboratories, Fort Worth, TX, USA
PSS36 Genentech, Inc, South San Francisco, CA, USA
PSS37 GSK, Wavre, Belgium
PSS38 PFSA, Boulogne, France
PSS39 None
PSS40 GSK Biologicals, Wavre, Belgium
PSS41 MSD, Madrid, Spain
PSS42 Italian Drug Agency (AIFA), Rome, Italy
PSS43 Merck Sharp & Dohme (Australia) Pty Limited, North Ryde, Sydney, Australia
PSS44 None
PSS45 Janssen-Cilag, Stockholm, Sweden
PSS46 Novartis Farmace´utica, S.A., Barcelona, Spain
PSU1 None
PSU2 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
PSU3 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
PSU4 Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
PSU5 None
PSU6 alcon france, Rueil-malmaison, France
PSU7 None
PSU8 Alcon research Ltd., Puurs, Belgium
PSU9 Amgen, Inc., Thousand Oaks, CA, USA
PSU10 Philips Healthcare, Hamburg, Germany
PSU11 Baxter, Maurepas, France
PSU12 Abbott Laboratories, Abbott Park, IL, USA
PSU13 Pfizer S.L.U, Madrid, Spain
PSU14 Teva Pharmaceuticals, Kansas City, MO, USA
PSU15 Bristol-Myers Squibb, Rueil-Malmaison, France
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PSU18 National Health Service, Madrid, Spain
PSU19 None
PSU20 AATM, Barcelona, Spain; FIS, Madrid, Spain
PSU21 None
PSU22 Alcon Laboratories, Fort Worth, TX, USA
PSU23 None
PSU24 None




PSY1 Janssen Global Services LLC, Beerse, Belgium
PSY2 Abbott Canada, St-Laurent, QC, Canada
PSY3 Johnson&Johnson Medical, Madrid, Spain
PSY4 Merck & Co, Whitehouse Station, NJ, USA
PSY5 Gruenenthal GmbH, Aachen, Germany
PSY6 Amgen, Thousand Oaks, CA, USA
PSY7 None
PSY8 Astellas Pharma, Madrid, Spain
PSY9 None
PSY10 Ipsen Pharma, Barcelona, Spain
PSY11 None
PSY12 Eli Lilly and Company, Indianapolis, IN, USA
PSY13 Eli Lilly and Company, Indianapolis, IN, USA
PSY14 Eli Lilly and Company, Indianapolis, IN, USA
PSY15 None
PSY16 Novo Nordisk A/S, Soborg, Denmark
PSY17 GlaxoSmithKline, Stockley Park, UK
PSY18 Pfizer Pharmaceutics Inc., Sa˜o Paulo, Brazil
PSY19 Amgen Europe, Zug, Switzerland
PSY20 Glaxo Smith Kline, Paris, France
PSY21 Eli Lilly and Company, Indianapolis, IN, USA
PSY23 Pfizer, Madrid, Spain
PSY24 Pfizer, Madrid, Spain
PSY25 None
PSY26 None
PSY27 Amgen (Europe) GmbH, Zug, Switzerland
PSY28 Baxter Healthcare, Harlow, UK
PSY29 Astellas, Vienna, Austria
PSY30 None
PSY31 Gru¨nenthal GmbH, Aachen, Germany
PSY32 Gru¨nenthal GmbH, Aachen, Germany
PSY33 GlaxoSmithKline, Moscow, Russia
PSY34 Vifor Ltd., Zurich, Switzerland
PSY35 Genesis Pharma SA, Athens, Greece
PSY36 National Institute for Health Research, Southampton, UK
PSY37 Ethicon, Paris, France
PSY38 GlaxoSmithKline, Research Triangle Park, NC, USA
PSY39 None
PSY40 Gru¨nenthal GmbH, Aachen, Germany
PSY41 Canadian Haemophilia Society, Toronto, ON, Canada
PSY42 Pfizer Deutschland DmbH, Berlin, AL, Germany
PSY43 Novo Nordisk A/S, Søborg, Denmark
PSY44 Eli Lilly and Company, Indianapolis, IN, USA
PSY45 UCB, Brussels, Belgium
PSY46 ZonMw, Den Haag, The Netherlands
PSY47 Baxter, Deerfield, IL, USA
PSY48 None
PSY49 PFSA, Castres, France
PSY50 PFSA, Castres, France
PSY51 None
PSY52 None
PSY53 Medco Health Solutions, Inc, Franklin Lakes, NJ, USA
PSY54 None
PSY55 Dutch Society for Hematology, Amsterdam, The Netherlands
PSY56 None
PSY57 CSD Medical Research, London, UK
PSY58 Pfizer, Madrid, Spain
PUK1 Astellas Pharma Europe Ltd., Staines, UK
PUK2 Takeda Global Research & Development Centre (Europe) Ltd., London, UK
PUK3 None
PUK4 Bristol Myer Squibb, Princeton, NJ, USA
PUK5 Bristol-Myers Squibb EU, Paris, France
PUK6 PFSA, Boulogne, France
PUK7 None
PUK8 Mitsubishi Tanabe Pharma America (MTPA), Inc., Warren, NJ, USA
PUK9 None
PUK10 Astellas Pharma Europe Ltd., Staines, UK
PUK11 Gambro Hospal GmbH, Gröbenzell, Germany
PUK12 Eli Lilly and Company, Indianapolis, IN, USA
PUK13 None
PUK14 None
PUK15 Amgen Europe, Zug, Switzerland
PUK16 Pfizer, Madrid, Spain
RS1 Association of British Pharmaceutical Industry, London, UK
RS2 Costello Medical Consulting Ltd., Cambridge, UK
RS3 Bristol-Myers Squibb, Braine L’Alleud, Belgium
RS4 Costello Medical Consulting, Cambridge, UK
UT1 None
UT2 None
UT3 Medical Research Council, London, UK
UT4 Gru¨nenthal GmbH, Aachen, Germany
VI1 ZonMw, DenHaag, The Netherlands
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